-
Fresenius Investigates Akorn FDA Compliance, Says Outcome May Affect Merger
Tuesday, February 27, 2018 - 9:12am | 282What Happened Akorn, Inc. (NASDAQ: AKRX) shares fell more than 30 percent Monday evening after Fresenius Kabi AG announced an independent investigation into alleged breaches of FDA data integrity requirements related to product development. Akorn later released a statement confirming its active...